Log in to search using one of your social media accounts:


Chiasma and FDA agree on new Phase III trial design for acromegaly drug

The US Food and Drug Administration (FDA) has agreed on biopharmaceutical firm Chiasma ’s new Phase III clinical trial (OPTIMAL) design to evaluate its octreotide capsules product candidate Mycapssa as a maintenance therapy to treat adults with acrome…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

More News: Acromegaly | Clinical Trials | Food and Drug Administration (FDA) | Pharmaceuticals